Pegylated liposomal doxorubicin in the treatment of cutaneous T-cell lymphoma.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of American Academy of Dermatology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1067/MJD.2001.109857PMID 11148501
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Pegylated, liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphoma: an update

  2009influential citation
• Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome.

  2008cites this paper
• Pegylated liposomal doxorubicin in the treatment of mycosis fungoides.

  2006influential citation
• Managing Cutaneous T-Cell Lymphoma and Related Diseases: An Update for Clinicians

  2006cites this paper
• Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials.

  2004cites this paper
• Management of the primary cutaneous lymphomas

  2003cites this paper
• Treatment of Cutaneous T Cell Lymphoma

  2002cites this paper
• Literature Alerts

  2001cites this paper
• Therapy options in cutaneous T-cell lymphoma

  2001cites this paper
• Literature Alerts

  2001cites this paper
• Clinical practice guidelines.

  1999cites this paper